Want to see AU:FRE full AI Analyst Report?
Firebrick Pharma Limited (FRE) AI Stock Analysis
Firebrick Pharma Limited
(ASX:FRE)
The score is held down primarily by weak financial performance—large losses, a sharp FY2026 revenue drop, and ongoing negative cash flow despite zero debt. Technicals are also soft with price below key moving averages and negative MACD, while valuation is constrained by negative earnings and no indicated dividend yield.
Firebrick Pharma Limited (FRE) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 8.32M
- Dividend Yield
- ―
- Average Volume (3M)
- 185.53K
- Price to Earnings (P/E)
- -2.3
- Beta (1Y)
- -0.16
- Revenue Growth
- -63.86%
- EPS Growth
- 4.00%
- Country
- Australia
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - General
Firebrick Pharma Limited Business Overview & Revenue Model
Company Description
Firebrick Pharma Limited, an enterprise established in 2012 and headquartered in Melbourne, Australia, is dedicated to the research, development, and market launch of Nasodine, a nasal spray treatment for the common cold, exclusively for the Australi...
Firebrick Pharma Limited Financial Statement Overview
Summary
Financials are dominated by sharp revenue decline (FY2026 down 72% YoY), deeply negative profitability (gross profit turned materially negative), and consistently negative operating/free cash flow. The main offsetting positive is zero debt, but ongoing losses and equity erosion keep financial strength weak.
Income Statement
12Very NegativeBalance Sheet
53NeutralCash Flow
18Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 106.03K | 106.03K | 293.42K | 14.52K | 830 | 4,124 |
| Gross Profit | -1.13M | -1.04M | 104.82K | -22.78K | 830 | 4,124 |
| EBITDA | -3.10M | -3.10M | -2.86M | -1.17M | -6.81M | -4.86M |
| Net Income | -3.06M | -3.06M | -2.63M | -1.18M | -6.80M | -3.80M |
Balance Sheet | ||||||
| Total Assets | 2.17M | 2.17M | 1.83M | 2.41M | 2.98M | 8.73M |
| Cash, Cash Equivalents and Short-Term Investments | 1.32M | 1.32M | 983.35K | 824.78K | 2.35M | 7.14M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 483.03K | 483.03K | 271.28K | 291.07K | 506.44K | 450.10K |
| Stockholders Equity | 1.68M | 1.68M | 1.56M | 2.12M | 2.48M | 8.28M |
Cash Flow | ||||||
| Free Cash Flow | -2.60M | -2.60M | -1.86M | -2.35M | -5.78M | -4.23M |
| Operating Cash Flow | -2.60M | -2.60M | -1.78M | -2.34M | -5.78M | -4.20M |
| Investing Cash Flow | 0 | 0 | -82.98K | -134 | -1,616 | -32.54K |
| Financing Cash Flow | 2.94M | 2.94M | 2.02M | 815.21K | 996.65K | 10.23M |
Firebrick Pharma Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:FRE, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 48.71 is Neutral, neither overbought nor oversold. The STOCH value of 62.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:FRE.
Firebrick Pharma Limited Peers Comparison
Overall Rating
AU:MYX59Neutral
AU:IMC46Neutral
AU:1AD44Neutral- AU:FRE44Neutral
AU:BOT41Neutral
AU:IDT41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:MYX | 59Neutral | AUD 208.00M | 8.19 | 6.58% | ― | -5.98% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:IMC | 46Neutral | AUD 12.91M | -3.10 | -31.88% | ― | 5.85% | 45.13% |
| AU:1AD | 44Neutral | AUD 6.42M | -0.87 | -6182.61% | ― | ― | 62.90% |
| AU:FRE | 44Neutral | AUD 8.32M | -2.25 | -169.20% | ― | -63.86% | 4.00% |
| AU:BOT | 41Neutral | AUD 27.63M | -0.31 | -118.74% | ― | 499.47% | 31.20% |
| AU:IDT | 41Neutral | AUD 18.20M | -6.88 | -13.81% | ― | 5.93% | 66.32% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:FRE | Firebrick Pharma Limited | 0.03 | -0.04 | -61.43% | |
| AU:MYX | Mayne Pharma Group Ltd. | 2.54 | -2.03 | -44.42% | |
| AU:IMC | Immuron Limited | 0.04 | -0.04 | -49.37% | |
| AU:1AD | AdAlta Ltd. | ― | ― | ― | |
| AU:IDT | IDT Australia Limited | 0.04 | -0.02 | -26.67% | |
| AU:BOT | Botanix Pharmaceuticals Limited | 0.01 | -0.12 | -92.31% |
Firebrick Pharma Limited Corporate Events
Firebrick Pharma Steps Up U.S. Push and Expands Nasodine Range
Firebrick Pharma reported its September 2026 quarter activities, highlighting a strategic push into the U.S. retail pharmacy market for its Nasodine products following strong online sales growth. The company appointed U.S.-based non-executive directo...
Firebrick Pharma Confirms Strategic Share Placement and Ongoing Product Development
Firebrick Pharma Limited has issued 20,907,143 ordinary fully paid shares at $0.035 per share as part of a strategic placement previously announced to the market. The company confirms the shares were issued without a disclosure document under the Cor...
Firebrick Pharma Seeks ASX Quotation for Over 20 Million New Shares
Firebrick Pharma Limited has applied for quotation of 20,907,143 ordinary fully paid shares on the ASX, with an issue date of 19 October 2026. The move formalizes the listing of these securities, potentially expanding the company’s tradable sha...
Firebrick Pharma Sets Virtual AGM to Approve Board, Incentives and Capital Mandate
Firebrick Pharma Limited has called its Annual General Meeting for 11 November 2026, to be held via a virtual meeting platform powered by Automic, allowing shareholders to watch, listen, ask questions and vote online. The board has set 9 November 202...
Firebrick Pharma Raises $732k to Accelerate Global Nasodine Expansion
Firebrick Pharma has secured approximately $732,000 in strategic equity investments via a placement of about 20.9 million shares at $0.035 per share, representing roughly 7.28% of its current shares on issue and priced at a notable premium to recent...
Firebrick Pharma Sets Phased U.S. Retail Push for Nasodine After Online Sales Surge
Firebrick Pharma has unveiled a plan to move beyond its current direct-to-consumer presence and enter the U.S. retail pharmacy market with its Nasodine products, following more than 200% growth in U.S. online sales in FY26. At a major U.S. pharmacy t...
Firebrick Pharma secures A$293,000 R&D tax incentive to support Nasodine product expansion
Firebrick Pharma has received an A$293,000 payment under Australia’s R&D Tax Incentive program for eligible research and development expenditure incurred in the 2025/26 financial year. The payment corresponds to A$673,000 in reported R&...
Firebrick Pharma Sets Virtual AGM and Director Nomination Deadline Amid Nasodine Expansion
Firebrick Pharma Limited has scheduled its Annual General Meeting for 11.00am AEDT on Wednesday, 11 November 2026, to be conducted as a virtual event via an online platform that will allow shareholders to watch, listen and vote remotely. The company...
Firebrick Pharma lodges ASX governance disclosures for 2026
Firebrick Pharma has lodged its Appendix 4G with the ASX for the financial year ended 30 June 2026, confirming that its corporate governance statement is current as at 31 August 2026 and available on its investor website. The filing indicates the com...
Firebrick Pharma Revenue Slides as Loss Widens and Asset Backing Erodes
Firebrick Pharma Limited reported a sharp decline in revenue from ordinary activities to $106,000 for the year ended 30 June 2026, down from $293,000 a year earlier, highlighting weaker commercial performance. The company operates in the pharmaceutic...
Firebrick Pharma Issues Shares to Consultant in Lieu of Fees
Firebrick Pharma Limited has issued 2,000,000 ordinary fully paid shares to a consultant in lieu of cash service fees, at an issue price of $0.026 per share, and has notified the market under section 708A of the Corporations Act. The company confirme...
Firebrick Pharma Seeks ASX Quotation for 2 Million New Shares
Firebrick Pharma Limited has lodged an application with the ASX for quotation of 2,000,000 ordinary fully paid shares under its FRE ticker. The new securities, issued on August 10, 2026, expand the company’s listed share base and reflect ongoin...
Firebrick Pharma Plans Placement of Up to 2 Million New Shares
Firebrick Pharma Limited has announced a proposed issue of up to 2,000,000 ordinary fully paid shares on the ASX under the code FRE. The securities are to be issued via a placement or other type of issue, with the proposed issue date set for 10 Augus...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 20, 2026